Bright Spot With Potential Shutdown: More FDA Staff Would Continue Working
Executive Summary
Nearly 70% of the FDA workforce would be retained, most from carryover user fee dollars, but potential morale problems loom if government funding runs out again.
You may also be interested in...
Coronavirus Notebook: WHO Backs MAb Combo, EMA Assessing Moderna Booster Jab
The COVID Moonshot project has received new funding for the open-source development of new candidate therapeutics, with results expected by the end of the year.
US FDA Lowers FY '22 PDUFA Fees Due to Hiring, Attrition Concerns
The agency reissued the user fee notice, saying fewer dollars were needed for new staff.
US FDA Publishes, Then Withdraws, PDUFA Rates Because Process ‘May Not Be Well Understood’
User fees for FY 2021 were set to increase nearly 11%, but could have gone even higher; a new notice will be issued but timing is unclear.